secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2026-08-04T12:05:06+00:00
Accession:  0001193125-26-331594
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics appoints Michelle Gilson to Board of Directors, as Audit Committee chair
--------------------------------------------------------------------------------

- Michelle Gilson appointed to Board effective August 1, 2026; also named chair of Audit Committee.
- Gilson, 34, was CFO of Arcellx until its acquisition by Gilead in April 2026.
- Prior roles include Senior Biotechnology Equity Research Analyst at Canaccord Genuity (Managing Director) and earlier at Jefferies, Nomura, Oppenheimer, Goldman Sachs.
- She will receive compensation per company's Non-Employee Director Compensation Policy; standard indemnification agreement.
- No arrangements, family relationships, or material interests in transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000119312526331594/0001193125-26-331594-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000119312526331594/d177572d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-331594

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer